Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Clobenztropine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.97 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.97 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.86 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.81 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.81 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.81 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.81 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.81 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.81 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.81 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.81 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.81 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.81 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.81 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.81 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.81 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.81 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.81 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clobenztropine SCHEMBL6678407 | 1.00 | MEN1 (1.00) | MEN1MAPTKMT2AGMNNLMNA | |
| Clobenztropine SCHEMBL6675824 | 1.00 | MEN1 (1.00) | MEN1MAPTKMT2AGMNNLMNA | |
| Clobenztropine SCHEMBL137213 | 0.99 | DRD3 (1.00) | MEN1MAPTKMT2AGMNNLMNA | |
| Clobenztropine SCHEMBL1152321 | 0.99 | DRD3 (1.00) | MEN1MAPTKMT2AGMNNLMNA | |
| Clobenztropine SCHEMBL1152891 | 0.99 | DRD3 (1.00) | MEN1MAPTKMT2AGMNNLMNA | |
| SCHEMBL5096472 | 0.93 | DRD3 (1.00) | MEN1MAPTKMT2AGMNNLMNA | |
| SCHEMBL1152029 | 0.93 | DRD3 (1.00) | MEN1MAPTKMT2AGMNNLMNA | |
| Benztropine SCHEMBL4152475 | 0.91 | DRD2 (0.97) | MEN1MAPTKMT2AGMNNLMNA | |
| Benztropine SCHEMBL35388 | 0.90 | DRD2 (1.00) | MEN1MAPTKMT2AGMNNLMNA | |
| Benztropine SCHEMBL8659140 | 0.90 | DRD2 (1.00) | MEN1MAPTKMT2AGMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 716 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724477-A1 | CIRCULARIZED ANTIBODY MOLECULES | Regeneron Pharmaceuticals, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-3565616-B1 | MEASURING ACCESS FLOW RATE BY USE OF BLOOD TREATMENT MACHINE | GAMBRO LUNDIA AB (SE) | 2025-11-19 | — | — | EP | claimed |
| CN-114548274-B | Rumor detection method and system based on multi-modal interaction | 齐鲁工业大学(山东省科学院) | 2025-04-29 | — | — | CN | claimed |
| CN-118932696-B | Technology for mint fiber antibacterial knitted underwear fabric | 浙江珊琪服饰有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-114821765-B | Human behavior recognition method based on fusion attention mechanism | 上海师范大学 | 2025-03-28 | — | — | CN | claimed |
| CN-119582879-A | Coaxial cable transmission method for airborne FC-AE-1553 network | 中国航空工业集团公司洛阳电光设备研究所 | 2025-03-07 | — | — | CN | claimed |
| CN-114690085-B | System and method for real-time magnetic field matching | 北京原子机器人科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| EP-4437385-B1 | COUPLING METHOD FOR REDUNDANT SERVO DEVICES OF AN ACTUATOR CONTROL SYSTEM, ASSOCIATED SYSTEM AND DEVICE | ZIPAIR (FR) | 2025-02-26 | — | — | EP | claimed |
| CN-119363193-A | Low orbit satellite beam scheduling optimization method and system based on simulated annealing algorithm | 上海交通大学 | 2025-01-24 | — | — | CN | claimed |
| CN-119205503-A | Attention mechanism-based Sentinel-2 remote sensing image super-resolution reconstruction method | 阳光农业相互保险公司 | 2024-12-27 | — | — | CN | claimed |
| CN-114014895-A | Ferrocenyl phosphine ligand compound and synthesis method thereof | 浙江大学 | 2022-02-08 | — | — | CN | claimed |
| CN-114024588-A | Method for analyzing influence of beam dispersion of antenna structure in ultra-wideband terahertz communication | 郑州大学 | 2022-02-08 | — | — | CN | claimed |
| CN-113960001-A | AutoQT-FRET method based on primary imaging measurement system correction factor and application thereof | 华南师范大学 | 2022-01-21 | — | — | CN | claimed |
| EP-2254579-B1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | ESTEVE LABOR DR (ES) | 2018-01-10 | — | — | EP | claimed |
| EP-1781272-B1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECHANICAL ALLODYNIA | ESTEVE LABOR DR (ES) | 2017-09-06 | — | — | EP | claimed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | claimed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | claimed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | claimed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| WO-2004041207-A2 | GHB TREATMENT METHODS | BAYLOR RESEARCH INSTITUTE (US) | 2004-05-21 | — | — | WO | claimed |